SNF5 promotes cell proliferation and immune evasion in non-small cell lung cancer

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;1–12.
   Google Scholar
• Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, et al. Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Front Oncol. 2020;10:605380.
   PubMed Web of Science ®Google Scholar
• Evison M. The current treatment landscape in the UK for stage III NSCLC. Br J Cancer. 2020;123:3–9.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–167.
   PubMed Web of Science ®Google Scholar
• Paluskievicz CM, Cao X, Abdi R, et al. T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol. 2019;10:2453.
   PubMed Web of Science ®Google Scholar
• Santaniello A, Napolitano F, Servetto A, et al. Tumour microenvironment and immune evasion in EGFR addicted NSCLC: hurdles and possibilities. Cancers (Basel). 2019;11:1–15.
   Web of Science ®Google Scholar
• Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39:149.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang R, Lin Z, et al. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38alpha/MYC/PD-L1 signaling in non-small cell lung cancer. J Hematol Oncol. 2020;13:99.
   PubMed Web of Science ®Google Scholar
• Song N, Li P, Song P, et al. MicroRNA-138-5p suppresses non-small cell lung cancer cells by targeting PD-L1/PD-1 to regulate tumor microenvironment. Front Cell Dev Biol. 2020;8:540.
   PubMed Web of Science ®Google Scholar
• Lin X, Lin K, Lin C, et al. Prognostic and clinicopathological value of PD-L2 in lung cancer: a meta-analysis. Int Immunopharmacol. 2021;91:107280.
   PubMed Web of Science ®Google Scholar
• Shang K, Wang Z, Hu Y, et al. Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion. Oncol Lett. 2020;19:3827–3838.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Takanashi S, Kanehira Y, et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91:964–971.
   PubMed Web of Science ®Google Scholar
• Xue Y, Meehan B, Fu Z, et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun. 2019;10:557.
   PubMed Web of Science ®Google Scholar
• Gupta M, Concepcion CP, Fahey CG, et al. BRG1 loss predisposes lung cancers to replicative stress and ATR dependency. Cancer Res. 2020;80:3841–3854.
   PubMed Web of Science ®Google Scholar
• Romero OA, Torres-Diz M, Pros E, et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2014;4:292–303.
   PubMed Web of Science ®Google Scholar
• Orvis T, Hepperla A, Walter V, et al. BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. Cancer Res. 2014;74:6486–6498.
   PubMed Web of Science ®Google Scholar
• Papadakis AI, Sun C, Knijnenburg TA, et al. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Res. 2015;25:445–458.
   PubMed Web of Science ®Google Scholar
• Ryokuhei Manda TK, Hamada K, Takenoshita S, et al. Absence of hSNF5/INI1 mutation in human lung cancer. Cancer Lett. 2000;153:57–61.
   PubMed Web of Science ®Google Scholar
• Choi SK, Kim MJ, You JS. SMARCB1 Acts as a Quiescent Gatekeeper for Cell Cycle and Immune Response in Human Cells. Int J Mol Sci. 2020;21:1–14.
   Web of Science ®Google Scholar
• Hong SH, Son KH, Ha SY, et al. Nucleoporin 210 serves a key scaffold for SMARCB1 in liver cancer. Cancer Res. 2021;81:356–370.
   PubMed Web of Science ®Google Scholar
• Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS one. 2010;5:e10312.
   PubMed Web of Science ®Google Scholar
• Baty F, Facompre M, Kaiser S, et al. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Am J Respir Crit Care Med. 2010;181:181–188.
   PubMed Web of Science ®Google Scholar
• Carugo A, Minelli R, Sapio L, et al. p53 is a master regulator of proteostasis in SMARCB1-deficient malignant rhabdoid tumors. Cancer Cell. 2019;35:204–220.e209.
   PubMed Web of Science ®Google Scholar
• Genovese G, Carugo A, Tepper J, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017;542:362–366.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu Q, Tao L, et al. Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway. Clin sci. 2020;134:1457–1472.
   Web of Science ®Google Scholar
• Wu Q, Madany P, Akech J, et al. The SWI/SNF ATPases are required for triple negative breast cancer cell proliferation. J Cell Physiol. 2015;230:2683–2694.
   PubMed Web of Science ®Google Scholar
• Tropée R, de la Peña Avalos B, Gough M, et al. The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer. Breast Cancer Res Treat. 2021;185:601–614.
   PubMed Web of Science ®Google Scholar
• Li CJ, Li YC, Zhang DR, et al. Signal transducers and activators of transcription 3 function in lung cancer. J Cancer Res Ther. 2013;9(Suppl 2):S67–73.
   PubMedGoogle Scholar
• Qian Y, Chai S, Liang Z, et al. KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. Mol Cancer. 2014;13:176.
   PubMed Web of Science ®Google Scholar
• Wei L, Liu Y, Ma Y, et al. C-X-C chemokine receptor 2 correlates with unfavorable prognosis and facilitates malignant cell activities via activating JAK2/STAT3 pathway in non-small cell lung cancer. Cell Cycle. 2019;18:3456–3471.
   PubMed Web of Science ®Google Scholar
• Batbold U, Liu JJ. Artemisia santolinifolia-mediated chemosensitization via activation of distinct cell death modes and suppression of STAT3/survivin-signaling pathways in NSCLC. Molecules. 2021;26:1–16.
   Web of Science ®Google Scholar
• Sp N, Kang DY, Lee JM, et al. Mechanistic insights of anti-immune evasion by nobiletin through regulating miR-197/STAT3/PD-L1 signaling in non-small cell lung cancer (NSCLC) cells. Int J Mol Sci. 2021;22:1–20.
   Web of Science ®Google Scholar
• Bu LL, Yu GT, Wu L, et al. STAT3 induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J Dent Res. 2017;96:1027–1034.
   PubMed Web of Science ®Google Scholar
• Zhou B, Yan J, Guo L, et al. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics. 2020;10:6530–6543.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang F, Du C, et al. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Cancer Lett. 2017;402:213–224.
   PubMed Web of Science ®Google Scholar
• Wu J, Keng VW, Patmore DM, et al. Insertional mutagenesis identifies a STAT3/Arid1b/β-catenin pathway driving neurofibroma initiation. Cell Rep. 2016;14:1979–1990.
   PubMed Web of Science ®Google Scholar